Is a packaging line that has come to a standstill in pharmaceutical production a sign of inefficiency?

In traditional industrial manufacturing, this question is often answered with a resounding ‘yes’. Overall Equipment Effectiveness (OEE) is regarded there as a key performance indicator, with the focus on high capacity utilisation and the continuous production of homogeneous batches.

However, the operating conditions in the pharmaceutical industry place this perspective within a broader context.

The requirements for modern pharmaceutical production have changed significantly in recent years. Alongside established high-volume products, specialised therapies, smaller batch sizes and an increasing product diversity are gaining in importance. At the same time, more complex supply chains and dynamic market demands require greater flexibility in production.

Against this backdrop, the ability to switch production lines quickly and safely is becoming increasingly important.

For us at Complex Pharmaceuticals, operational excellence therefore does not mean simply maximising capacity utilisation, but rather, and in particular, maintaining control over process variability.

In this context, a planned machine shutdown as part of a format change does not represent a loss of efficiency, but rather forms part of a controlled and necessary production process. The key factor here is the ability to consistently optimise set-up and changeover times whilst adhering to the highest quality and GMP standards.

Modern, modular plant designs enable flexible switching between different dosage forms such as ampoules, vials, infusion bags or injection systems – in a reproducible, efficient and quality-assured manner.

Success in a GMP-regulated environment should therefore not be defined solely by volume metrics, but by the ability to balance flexibility, quality and supply security.

#Pharmaindustry #GMP #SupplyChain #OperativeExzellenz #ComplexPharmaceuticals #LifeSciences